| CPC A61K 36/064 (2013.01) [A61K 9/28 (2013.01); A61K 9/4825 (2013.01); A61K 9/5042 (2013.01); A61K 31/327 (2013.01); A61K 35/742 (2013.01); A61K 35/748 (2013.01); A61K 38/44 (2013.01); A61P 31/04 (2018.01)] | 20 Claims |
|
1. An oral formulation for oxygenating an intestinal region of a subject, comprising:
an oxygen prodrug;
a plurality of yeast cells comprising an enzyme configured to act on the prodrug and convert it to an active agent upon contacting the prodrug,
wherein the enzyme controls the rate of conversion of the prodrug to oxygen;
a first soluble coating surrounding the oxygen prodrug and separating the oxygen prodrug from the plurality of yeast cells;
a second soluble coating surrounding the plurality of yeast cells and the coated oxygen prodrug;
an insoluble, semipermeable coating having a lumen, wherein the coated plurality of yeast cells surrounding the coated oxygen prodrug resides within the lumen, and
an enteric coating surrounding the oral formulation,
wherein the insoluble, semipermeable coating has a pore size that prevents a majority of the enzyme from diffusing across the coating out of the lumen and prevents a majority of digestive enzymes from diffusing across the coating into the lumen,
wherein the pore size is sufficient to allow water from an intestinal region to diffuse across any portion of the semipermeable coating to contact the oxygen prodrug and to allow oxygen to be generated to diffuse across any portion of the semipermeable coating into the intestinal region of the subject,
wherein when orally administered to the subject, the first and second soluble coating dissolve within the intestinal region and allow the oxygen prodrug and plurality of yeast cells to contact one another,
wherein the contacting of the plurality of yeast cells and the oxygen prodrug allows the enzyme from the yeast cells to convert the oxygen prodrug to oxygen, thereby oxygenating the intestinal region, and
wherein the oral formulation is in solid form.
|